前列腺癌逐步成为影响男性健康的主要恶性肿瘤之一，高危前列腺癌转移和复发的风险较高。因此，明确前列腺癌危险因素的等级，对于治疗方式的选择和预后的判断均有重要的指导意义。目前临床上传统的影像学手段在前列腺癌诊断中存在一定的局限性，而前列腺癌特异性膜抗原（PSMA）标记的正电子发射断层扫描（PET）的问世，为高危前列腺癌的诊疗提供了重要参考。作者对目前PSMA PET在高危前列腺癌患者的诊断、治疗及预后的临床管理中的应用进展作一综述。

[1] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
[2] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[3] SIEGEL R L,MILLER K D,JEMAL A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[4] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[5] ITO K.Prostate cancer in Asian men[J].Nat Rev Urol,2014,11(4):197-212.
[6] 叶定伟,朱耀.中国前列腺癌的流行病学概述和启示[J].中华外科杂志,2015,53(4):249-252.
[7] 韩苏军,张思维,马建辉,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤杂志,2013,18:330-334.
[8] AGARWAL P K,SADETSKY N,KONETY B R,et al.Treatment failure after primary and salvage therapy for prostate cancer:likelihood,patterns of care,and outcomes[J].Cancer,2008,112(2):307-314.
[9] MERGLEN A,SCHMIDLIN F,FIORETTA G,et al.Short-and long-term mortality with localized prostate cancer[J].Arch Intern Med,2007,167(18):1944-1950.
[10] 那彦群,叶章群,孙颖浩,等.2014版中国泌尿外科疾病诊断治疗指南手册[M].北京:人民卫生出版社,2014:61-81.
[11] CHUGHTAI B,MIAN B M.High risk prostate cancer:evolving definition and approach to management[J].Can J Urol,2008,15(6):4375-4380.
[12] MATSUMOTO T,HATAKEYAMA S,OOKUBO T,et al.Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy:a multi-institutional analysis[J].Med Oncol,2017,34(12):190.
[13] MAURER T,EIBER M,SCHWAIGER M,et al.Current use of PSMA PET in prostate cancer management[J].Nat Rev Urol,2016,13(4):226-235.
[14] LEEK J,LENCH N,MARAJ B,et al.Prostate-specific membrane antigen:evidence for the existence of a second related human gene[J].Br J Cancer,1995,72(3):583-588.
[15] YAO V,BERKMAN C E,CHOI J K,et al.Expression of prostate-specific membrane antigen (PSMA),increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate,folic acid[J].Prostate,2010,70(3):305-316.
[16] MARCHAL C,REDONDO M,PADILLA M,et al.Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].Histol Histopathol,2004,19(3):715-718.
[17] KINOSHITA Y,KURATSUKURI K,LANDAS S,et al.Expression of prostate-specific membrane antigen in normal and malignant human tissues[J].World J Surg,2006,30(4):628-636.
[18] FUNG E K,CHEAL S M,FAREEDY S B,et al.Targeting of radiolabeled J591 antibody to PSMA-expressing tumors:optimization of imaging and therapy based on non-linear compartmental modeling[J].EJNMMI Res,2016,6(1):7.
[19] SODEE D B,MALGURIA N,FAULHABER P,et al.Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer.The ProstaScint Imaging Centers[J].Urology,2000,56(6):988-993.
[20] MEASE R C,FOSS C A,POMPER M G.PET imaging in prostate cancer:focus on prostate-specific membrane antigen[J].Curr Top Med Chem,2013,13(8):951-962.
[21] OSBORNE J R,AKHTAR N H,VALLABHAJOSULA S,et al.Prostate-specific membrane antigen-based imaging[J].Urol Oncol,2013,31(2):144-154.
[22] BOUCHELOUCHE K,TURKBEY B,CHOYKE P L.PSMA PET and radionuclide therapy in prostate cancer[J].Semin Nucl Med,2016,46(6):522-535.
[23] CHO S Y,GAGE K L,MEASE R C,et al.Biodistribution,tumor detection,and radiation dosimetry of 18F-DCFBC,a low-molecular-weight inhibitor of prostate-specific membrane antigen,in patients with metastatic prostate cancer[J].J Nucl Med,2012,53(12):1883-1891.
[24] SILVER D A,PELLICER I,FAIR W R,et al.Prostate-specific membrane antigen expression in normal and malignant human tissues[J].Clin Cancer Res,1997,3(1):81-85.
[25] ZAMBOGLOU C,SCHILLER F,FECHTER T,et al.(68) Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer:A Voxel-Wise comparison[J].Theranostics,2016,6(10):1619-1628.
[26] TURKBEY B,BROWN A M,SANKINENI S,et al.Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer[J].CA Cancer J Clin,2016,66(4):326-336.
[27] ZAMBOGLOU C,DRENDEL V,JILG C A,et al.Comparison of ⁶⁸Ga-HBED-CC PSMA PET/CT and multiparametric MRI for gross tumor volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology[J].Theranostics,2017,7(1):228-237.
[28] MARTORANA G,SCHIAVINA R,CORTI B,et al.11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy[J].J Urol,2006,176(3):954-960.
[29] EIBER M,WEIRICH G,HOLZAPFEL K,et al.Simultaneous ⁶⁸Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer[J].Eur Urol,2016,70(5):829-836.
[30] HOVELS A M,HEESAKKERS R A,ADANG E M,et al.The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:a meta-analysis[J].Clin Radiol,2008,63(4):387-395.
[31] MAURER T,GSCHWEND J E,RAUSCHER I,et al.Diagnostic efficacy of (68) Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer[J].J Urol,2016,195(5):1436-1443.
[32] 马宏青,葛京平,魏武,等.PSA、ECT骨显像诊断前列腺癌骨转移的临床价值[J].中华男科学杂志,2002,8(4):289-291.
[33] PYKA T,OKAMOTO S,DAHLBENDER M,et al.Comparison of bone scintigraphy and ⁶⁸Ga-PSMA PET for skeletal staging in prostate cancer[J].Eur J Nucl Med Mol Imaging,2016,43(12):2114-2121.
[34] JANSSEN J C,MEINER S,WOYTHAL N,et al.Comparison of hybrid ⁶⁸Ga-PSMA PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients:Additional value of morphologic information from low dose CT[J].Eur Radiol,2018,28(2):610-619.
[35] JI J,YUAN H,WANG L,et al.Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk?A single center prospective study[J].J Surg Res,2012,178(2):779-784.
[36] ÖBEK C,DOĞANCA T,DEMIRCI E,et al.The accuracy of ⁶⁸Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer[J].Eur J Nucl Med Mol Imaging,2017,44(11):1806-1812.
[37] HRUBY G,EADE T,EMMETT L,et al.⁶⁸Ga-PSMA PET/CT staging prior to definitive radiation treatment for prostate cancer[J].Asia Pac J Clin Oncol,2018,14(4):343-346.
[38] CALAIS J,CZERNIN J,CAO M,et al.⁶⁸Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL:Impact on salvage radiotherapy planning[J].J Nucl Med,2018,59(2):230-237.
[39] BLUEMEL C,LINKE F,HERRMANN K,et al.Impact of ⁶⁸Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy[J].EJNMMI Res,2016,6(1):78.
[40] HABL G,SAUTER K,SCHILLER K,et al.⁶⁸Ga-PSMA PET for radiation treatment planning in prostate cancer recurrences after surgery:Individualized medicine or new standard in salvage treatment[J].Prostate,2017,77(8):920-927.
[41] EMMETT L,VAN LEEUWEN P J,NANDURKAR R,et al.Treatment outcomes from ⁶⁸Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy:Prognostic value of a negative PSMA PET[J].J Nucl Med,2017,58(12):1972-1976.
[42] RAUSCHER I,DVWEL C,WIRTZ M,et al.Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer:correlation with histopathology and clinical follow-up[J].BJU Int,2017,120(1):40-47.
[43] ZUMSTEG Z S,DASKIVICH T J,SANDLER H M.Salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy[J].J Clin Oncol,2016,34(32):3829-3833.
[44] CALOPEDOS R J S,CHALASANI V,ASHER R,et al.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer:a systematic review and meta-analysis[J].Prostate Cancer Prostatic Dis,2017,20(3):352-360.
[45] KRATOCHWIL C,BRUCHERTSEIFER F,GIESEL F L,et al.225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer[J].J Nucl Med,2016,57(12):1941-1944.
[46] CARLAW K R,WOO H H.Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016[J].Prostate Int,2017,5(4):130-134.
[47] BAUMANN R,KONCZ M,LUETZEN U,et al.Oligometastases in prostate cancer:Metabolic response in follow-up PSMA PET-CTs after hypofractionated IGRT[J].Strahlenther Onkol,2018,194(4):318-324.
[48] KIM J H,KIM B J,JANG H J,et al.Comparison of the RECIST and EORTC PET criteria in the tumor response assessment:a pooled analysis and review[J].Cancer Chemother Pharmacol,2017,80(4):729-735.
[49] AIDE N,LASNON C,VEIT-HAIBACH P,et al.EANM/EARL harmonization strategies in PET quantification:from daily practice to multicentre oncological studies[J].Eur J Nucl Med Mol Imaging,2017,44(Suppl 1):17-31.
[50] EIBER M,HERRMANN K,CALAIS J,et al.Prostate cancer molecular imaging standardized evaluation (PROMISE):Proposed miTNM classification for the interpretation of PSMA-Ligand PET/CT[J].J Nucl Med,2018,59(3):469-478.
[51] AFSHAR-OROMIEH A,ZECHMANN C M,MALCHER A,et al.Comparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer[J].Eur J Nucl Med Mol Imaging,2014,41(1):11-20.
[52] AFSHAR-OROMIEH A,HOLLAND-LETZ T,GIESEL F L,et al.Diagnostic performance of ⁶⁸Ga-PSMA-11(HBED-CC) PET/CT in patients with recurrent prostate cancer:evaluation in 1007 patients[J].Eur J Nucl Med Mol Imaging,2017,44(8):1258-1268.